Skip to content

Abstract B127: Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma

Sep 2026 · Cancer Research · 0 citations

TL;DR

It is demonstrated that dual BET and CDK9 inhibition promotes transcriptional pausing and suppresses key regulators in transcriptionally driven cancers, as well as demonstrating on-target transcriptional inhibition.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality and comprises molecular subtypes characterized by MYC amplification (14%) or MYC overexpression (40%), both of which drive tumor proliferation, metabolic reprogramming, and cellular plasticity. MYC dysregulation is associated with poor clinical outcomes and resistance, but its direct targeting remains a challenge. Here, we investigate the response of a patient-derived cancer organoid (PCO) model of PDAC as a function of MYC amplification to evaluate the synthetic lethality of dual transcriptional inhibition through BET inhibition (ZEN3694) and CDK9 inhibition (SLS009). A MYC-amplified PCO (Copy number 35) was treated with ZEN3694 (500nM), SLS009 (200nM) or the combination. Apoptosis and necrosis were assessed at 72h with caspase-3/7 and TO-PRO staining, respectively with cycloheximide (200 μM) as a positive control. One-way ANOVA followed by Tukey's post hoc test was used to compare mean percentage of area stained between treatment groups. Dose-response combination matrices were generated and viability was measured at 144h using 3D CellTiter-Glo (CTG, 50% v/v). Drug Synergy was quantified via SynergyFinder 3.0 (Zero Interaction Potency (ZIP), Bliss Independence (Bliss), Highest Single Agent (HSA)). Protein was isolated at 24h for Western blot analysis of total and Ser2/Ser5-phosphorylated RNA polymerase II, MYC and MCL-1. Blots were imaged using the LI-COR Odyssey imaging system and quantified with Image Studio software. Following 72h treatment with SLS009 or ZEN3694 there was an observed mean Caspase-3/7 stained area of 14.78% and 5.178%, and mean TO-PRO staining of 15.68% and 5.131%, respectively. The combination of ZEN3694 and SLS009 further increased Caspase-3/7 staining to 25.65% (p< 0.001) and TO-PRO staining to 22.84% (p< 0.001). Dual treatment achieved synergy scores ranging between 17-21 indicating increased therapeutic activity. Western blot analysis showed on-target activity for the combination including reduced phosphorylation of RNA Pol II (Ser2/Ser5) (p< 0.0002 and p< of 0.0015) and decrease in T-Rpb1 (NTD) (p< 0.0162) consistent with transcriptional pausing. Furthermore, expression of short-lived transcription factors MYC and MCL-1 were both downregulated (both p< 0.0001). This study demonstrates that dual BET and CDK9 inhibition promotes transcriptional pausing and suppresses key regulators in transcriptionally driven cancers. Additionally, combining ZEN3694 and SLS009 exhibited in vitro synergy in and induced both apoptosis and necrosis, as well as demonstrating on-target transcriptional inhibition. Notably, these effects were achieved using ZEN3694 at a concentration substantially below physiological values, suggesting that SLS009 can potentiate the activity of BET inhibition. Ongoing studies are exploring this combination in other PDO models with diverse mutational backgrounds, with future work aimed at validating these findings in vivo to assess therapeutic efficacy and toxicity. Paulina N. Esguerra, Michela Cadarso, Sasha Livingwell, Md Shahadat Hossan, Olivia Wong, Jeremy D. Kratz. Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B127.

View source

Similar papers

Sep 2026

Abstract B043: Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma

A patient-derived cancer organoid (PCO) model that is MYC-amplified is examined to assess the activity of combining CDK9 inhibition (SLS009) with tricomplex RAS (ON inhibitors) studying both RMC-6236 and RMC-9805 and significantly augments the induction of apoptosis and necrosis compared to single agent activity.

Michela Cadarso, Paulina N. Esguerra, Lauryn E. Flannagan et al. · 0 citations
Sep 2026

Abstract A036: Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with an unmet need for novel precision based therapies. While KRAS canonically drives tumor progression, MYC amplification has emerged as a critical downstream resistance mechanism. Efforts have been made to elucidate the role of MYC amplification in PDAC...

Audrey G. Sawyer, Lauryn E. Flannagan, Paulina N. Esguerra et al. · 0 citations
Sep 2026

Abstract B087: Impact of RAS inhibition on T cell maturation in the PDAC microenvironment

It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.

Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al. · 0 citations
#gene editing Sep 2026

Abstract B067: Dissection of the in vitro response landscape in PDAC under KRAS inhibition reveals co-occurring conserved and adaptive transcription programs

In vitro perturbation is used to decipher the early transcriptional response programs in patient-derived 2D and 3D cell models of PDAC to KRAS inhibition and identify a robust RNA-based signature with potential utility for pharmacodynamic monitoring and the study of adaptive resistance.

H. Schürmann, J. Asche, S. Liffers et al. · 0 citations
Sep 2026

Abstract B059: Loss of Cullin-RING Ligase 5 mediates resistance to RAS inhibition in pancreatic cancer

How selective modulation of protein degradation governs adaptive resistance to RAS inhibition governs adaptive resistance to RAS inhibition and provide a framework for developing rational combination strategies to improve the durability of RAS-targeted therapies in PDAC is defined.

Cassandra S. Markham, Ilze M. Olivi Gomes, Yi Di et al. · 0 citations
Sep 2026

Abstract B126: Targeting USP36 as a therapeutic strategy for high-MYC expressing pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by poor therapeutic response and aggressive disease progression driven heavily by the c-MYC oncoprotein. Ubiquitin-specific protease 36 (USP36) is a nucleolar deubiquitinating enzyme that enhances the stability of criti...

Assmaa ElSheikh, Ping-Chuan Zhang, Xiao-Yan Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.